Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis

Not Applicable

Active, not recruiting

• Conditions: Cellulitis
• Interventions: Other: Dermatology consult

• Registration Number: NCT01706913
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

This is a randomized, controlled study to compare patients evaluated and managed by internal medicine hospitalists alone versus patients who are additionally evaluated by a dermatologist when they are admitted to the hospital, aiming to demonstrate that hospital admissions for cellulitis that involve early dermatology consultation will reduce hospital length of stay, readmission rates, prevalence of pseudocellulitis, cost, and antibiotic usage. The hypothesis of this study is that obtaining inpatient dermatology consultations, within 24 hours of a patient being admitted to the hospital for cellulitis, will reduce the length of stay, readmission rate, cost, and antibiotic usage of the patient"s admission as well as properly evaluate and diagnose patients with pseudocellulitis. The primary objective will be to measure the difference in the length of stay for patients who are randomized to a dermatology consultation within 24 hours of hospital admission (active arm) versus being managed by an internal medicine hospitalist alone, as is the standard of care (control arm). The length of stay for each arm will be assessed once the study has been completed. The secondary endpoint will be to measure readmission rates for cellulitis after patients are discharged from the hospital. An additional endpoint will be to determine if antibiotic usage differs between patients randomized to a dermatology consultation and those not. Exploratory analyses will assess the percentage of patients with a concomitant known predisposing factor for recurrent cellulitis such as lymphedema, leg ulceration, tinea pedis, or onychomycosis, as well as the association of fever \>100.5 F and a history of a prior episode of cellulitis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-09-25
• Study Start: 2012-10
• Study First Submitted QC: 2012-10-12
• Study First Posted: 2012-10-15
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-04
• Last Update Posted: 2023-04-06
• Primary Completion: 2024-12
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 246

Inclusion Criteria

• Able to understand and sign informed consent
• Able to complete study and comply with study procedures
• Presumed clinical diagnosis of cellulitis by medicine team

Exclusion Criteria

• Have a known postoperative site infection or abscess
• Have a human/animal bite
• Have known osteomyelitis
• Have a hardware/line infection
• Are under the age of 18
• Have a history of transplantation less than six months after initial transplant and/or if they have had an episode of acute rejection in the last 90 days
• Known use of antithymocyte globulin or campath in the last 6 months or more than 20 mg/day of prednisone for more than 30 days -
• Are a known prisoner.
• Are decisionally-impaired.
• Have abnormal vital signs defined as systolic blood pressure <90 mmHg, diastolic blood pressure <80 mmHg, heart rate greater than 90 beats per minute or less than 50 beats per minute, respiratory rate greater than 20, or temperature > 100.5 F.
• Are known to be pregnant.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dermatology Consult	Dermatology consult	The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.

Primary Outcome Measures

Name	Time	Method
Antibiotic usage	2 weeks after discharge from hospital stay	We will be measuring the difference between antibiotic usage in patients in the control group as compared with the treatment group

Secondary Outcome Measures

Name	Time	Method
Length of hospital stay	Will be measured at day of patient discharge	We will be comparing the length of admission between the control group and the treatment group to assess whether a dermatology consult has any impact on the length of a patient's hospital stay.

Trial Locations

Locations (1)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States